Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced cancer? early trial tests MK-3120

NCT ID NCT06818643

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 6 times

Summary

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at whether the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MK-3120 (also known as SKB410), a biologic drug given by IV infusion
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors who have no other choices left.
What could go wrong
This is an early phase 1/2 trial, so the main goal is safety, not yet proof of effectiveness. The drug may cause side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments * If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART) * If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * If hepatitis C virus (HCV) infected, must have undetectable HCV viral load Exclusion Criteria: * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled significant cardiovascular disease or cerebrovascular disease * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage * Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Known additional malignancy that is progressing or has required active treatment within the past 2 years * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Active infection requiring systemic therapy, with exceptions * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Has HBV or HCV infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors Malignant neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    49 sites in 12 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Amsterdam UMC, locatie VUmc ( Site 0093)

    RECRUITING

    Amsterdam, North Holland, 1081HV, Netherlands

  • Ankara Bilkent Şehir Hastanesi. ( Site 0131)

    RECRUITING

    Çankaya, Ankara, 06800, Turkey (Türkiye)

  • Ankara University Health Practice and Research Hospitals ( Site 0134)

    RECRUITING

    Ankara, 06620, Turkey (Türkiye)

  • Asan Medical Center ( Site 0153)

    RECRUITING

    Seoul, 05505, South Korea

  • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Cancer Institute Hospital of JFCR ( Site 0192)

    RECRUITING

    Koto, Tokyo, 135-8550, Japan

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054)

    RECRUITING

    Rennes, Ille-et-Vilaine, 35000, France

  • Centre Oscar Lambret ( Site 0051)

    RECRUITING

    Lille, Nord, 59000, France

  • Centro de Estudios Clínicos SAGA ( Site 0033)

    RECRUITING

    Santiago, Region M. de Santiago, 7500653, Chile

  • Chi Mei Medical Center ( Site 0162)

    RECRUITING

    Tainan, Tainan, 71004, Taiwan

  • Chongqing Cancer Hospital ( Site 0186)

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • Erasmus Medisch Centrum ( Site 0092)

    RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

  • FALP ( Site 0031)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Gustave Roussy ( Site 0050)

    RECRUITING

    Villejuif, Val-de-Marne, 94800, France

  • HOSPITAL CLÍNIC DE BARCELONA ( Site 0112)

    RECRUITING

    Barcelona, Catalonia, 08036, Spain

  • Hacettepe Universite Hastaneleri ( Site 0130)

    RECRUITING

    Ankara, 6230, Turkey (Türkiye)

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111)

    RECRUITING

    Madrid, Madrid, Comunidad de, 28040, Spain

  • Hospital Universitario Virgen de la Victoria ( Site 0114)

    RECRUITING

    Málaga, 29016, Spain

  • Hunan Cancer Hospital ( Site 0181)

    RECRUITING

    Changsha, Hunan, 410013, China

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0113)

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Institut Paoli Calmettes ( Site 0053)

    RECRUITING

    Marseille, Bouches-du-Rhone, 13273, France

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Koc University, School of Medicine ( Site 0133)

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • NEXT Oncology ( Site 1010)

    RECRUITING

    Austin, Texas, 78758, United States

  • NEXT Oncology ( Site 1011)

    RECRUITING

    Houston, Texas, 77054, United States

  • NEXT Oncology ( Site 1012)

    RECRUITING

    Irving, Texas, 75039, United States

  • Narodowy Instytut Onkologii ( Site 0100)

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital East ( Site 0190)

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital ( Site 0161)

    RECRUITING

    Tainan, 704, Taiwan

  • National Taiwan University Hospital ( Site 0160)

    RECRUITING

    Taipei, 10002, Taiwan

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090)

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0191)

    RECRUITING

    Osaka, 541-8567, Japan

  • Peking University First Hospital ( Site 0180)

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

  • Pontificia Universidad Catolica de Chile ( Site 0032)

    RECRUITING

    Santiago, Region M. de Santiago, 8330032, Chile

  • Pratia MCM Krakow ( Site 0106)

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 30-727, Poland

  • Pratia Poznan ( Site 0105)

    RECRUITING

    Poznan, Greater Poland Voivodeship, 60-192, Poland

  • Rabin Medical Center ( Site 0081)

    RECRUITING

    Petah Tikva, 4941492, Israel

  • Radboudumc ( Site 0091)

    RECRUITING

    Nijmegen, Gelderland, 6525 GA, Netherlands

  • Rambam Health Care Campus ( Site 0082)

    RECRUITING

    Haifa, 3109601, Israel

  • Samsung Medical Center ( Site 0152)

    RECRUITING

    Seoul, 06351, South Korea

  • Seoul National University Hospital ( Site 0150)

    RECRUITING

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 0151)

    RECRUITING

    Seoul, 03722, South Korea

  • Sheba Medical Center ( Site 0080)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0104)

    RECRUITING

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • The First Hospital of Jilin University ( Site 0185)

    RECRUITING

    Changchun, Jilin, 130021, China

  • The University of Alabama at Birmingham ( Site 1005)

    RECRUITING

    Birmingham, Alabama, 35249, United States

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)

    RECRUITING

    Miami, Florida, 33136, United States

  • Virginia Commonwealth University ( Site 1008)

    RECRUITING

    Richmond, Virginia, 23219, United States

  • West China Hospital Sichuan University ( Site 0187)

    RECRUITING

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.